peptide0 listings

Orforglipron

Orforglipron (LY3502970)

Oral non-peptide GLP-1 receptor agonist. Weight and glycemic research.

Weight researchGlycemic researchMetabolic research

/ research index

The research base

Research Maturity

★★★★☆

4/5 — Volume of studies

Evidence Strength

★★★★☆

4/5 — Quality of evidence

First oral small-molecule GLP-1 agonist to reach late-stage trials, offering pill-based administration without injection.

/ mechanism of action

How it works

Non-peptide GLP-1 receptor agonist. Orally bioavailable unlike injectable GLP-1 peptides, enabling daily oral dosing.

/ research dosing

Common research protocols

Range

3 → 12 → 36 mg/day (trial titration range)

Frequency

Once daily, oral

Route

Oral

Cycle

Titrate up over weeks

Research notes

Oral administration is the key differentiator from injectable GLP-1s. Phase 2 trials titrated to 36mg/day. No food/water restrictions noted in later formulations.

References

PMID: 37366315 →ClinicalTrials.gov NCT05051579

FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.

/ standalone use

As a solo compound

Standalone oral use. No reconstitution required.

/ side effects

What to know

GI effects (nausea, vomiting, diarrhea) dose-dependent, consistent with GLP-1 class.

/ timeline

Realistic expectations

Effects build over weeks to months

FOR RESEARCH USE ONLY. Orforglipron is intended for laboratory research and not for human consumption.